n.a. (CLTX)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)

Celsus Therapeutics (CLTX) Stock Hits One-Year Low Following Disappointing Trial Results

Shares of Celsus Therapeutics (CLTX) plunged more to a 52-week low in morning trading Tuesday after the biotech company announced the results of its dermatitis treatment in a mid-stage trial.

Celsus Therapeutics Announces That The Phase II Trial Of MRX-6 Cream 2% In Pediatric Atopic Dermatitis Did Not Reach Primary Endpoint

MRX-6 Cream Did Not Demonstrate Separation From Vehicle in Primary Endpoint of Percent Improvement in the Investigator's Global Assessment

Celsus Therapeutics Completes Enrollment Of Phase II Trial Of MRX-6 Cream 2% In Pediatric Atopic Dermatitis

Topline Data From Double-Blind Portion of Trial Expected by End of February, 2015

Celsus Therapeutics Announces FDA Allowance Of IND For Clinical Development Of MRX-6 Cream In Atopic Dermatitis

Phase II Dose Ranging Clinical Trial in Atopic Dermatitis Expected to Begin in First Quarter of 2015